Prothena Corporation plc has now earned $150 million to date of the $1,200 million total eligible milestone payments from Novo Nordisk. Prothena Corporation plc earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial evaluating coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021.
Under the terms of the acquisition agreement, Prothena is eligible to receive up to $1,200 million upon achievement of clinical development and sales milestones, including $150 million earned to date.
